In this video, Motley Fool health-care bureau chief Brenton Flynn takes a closer look at Dendreon (NASDAQ: DNDN), a company that has underperformed recently, to shareholders' chagrin. Brenton looked at the company's recent SEC filings and gives us a few interesting pieces of information about the company he gleaned from them. For one thing, the company had been sitting on some zero-cost antigen inventory, and benefiting from that wasn't being recognized as an expense. Second, the company made a sharp move by selling its royalty rights to Merck's (NYSE: MRK) hepatitis C drug Victrelis last year for $125 million.
Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
